References
- Grimm NB, Faeth SH, Golubiewski NE et al. Global change and the ecology of cities. Science319(5864), 756–760 (2008).
- Wolfe ND, Dunavan CP, Diamond J. Origins of major human infectious diseases. Nature447(7142), 279–283 (2007).
- Bloom DE, Canning D, Weston M. The value of vaccination. World Economics6, 15–39 (2005).
- Struck MM. Vaccine R&D success rates and development times. Nat. Biotechnol.14(5), 591–593 (1996).
- Jadhav S, Datla M, Kreeftenberg H, Hendriks J. The Developing Countries Vaccine Manufacturers’ Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries. Vaccine26(13), 1611–1615 (2008).
- United States Government Accountability Office. Project Bioshield: actions needed to avoid repeating past problems with procuring new anthrax vaccine and managing the stockpile of licensed vaccine. GAO-08–88 (2007).
- World Health Organization. The World Health Report 2007 – a safer future: global public health security in the 21st century. WHO, Geneva, Switzerland (2008).
- Holmes KV. Structural biology. Adaptation of SARS coronavirus to humans. Science309(5742), 1822–1823 (2005).
- Lee J-W, McKibbin WJ. Globalization and disease: the case of SARS. Asian Economic Papers3, 113–131 (2004).
- Zhu Z, Dimitrov AS, Chakraborti S et al. Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses. Expert. Rev. Anti Infect. Ther.4(1), 57–66 (2006).
- Giritch A, Marillonnet S, Engler C et al. Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proc. Natl Acad. Sci. USA103(40), 14701–14706 (2006).
- Gerdts V, Littel-van den Hurk SD, Griebel PJ, Babiuk LA. Use of animal models in the development of human vaccines. Future Microbiol.2, 667–675 (2007).
- Judenhofer MS, Wehrl HF, Newport DF et al. Simultaneous PET–MRI: a new approach for functional and morphological imaging. Nat. Med.14(4), 459–465 (2008).
- Hamaguchi I, Imai J, Momose H et al. Application of quantitative gene expression analysis for pertussis vaccine safety control. Vaccine26(36), 4686–4696 (2008).
- Mizukami T, Imai J, Hamaguchi I et al. Application of DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation. Vaccine26(18), 2270–2283 (2008).
- Sariol CA, Munoz-Jordan JL, Abel K et al. Transcriptional activation of interferon-stimulated genes but not of cytokine genes after primary infection of rhesus macaques with dengue virus type 1. Clin. Vaccine Immunol.14(6), 756–766 (2007).
- Simmons CP, Popper S, Dolocek C et al. Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J. Infect. Dis.195(8), 1097–1107 (2007).
Websites
- Centers for Disease Control and Prevention. Current vaccine shortages & delays 2008 www.cdc.gov/vaccines/vac-gen/shortages/default.htm
- Vizier Project Team. Vizier Project 2008 www.vizier-europe.org